Marc Carrier

Active 1989–2026

Also published as
Marc CARRIER
208
Papers
23,387
Citations
76
h-index
178
i10-index

Citations

Citations per year for Marc Carrier1989: 4 citations1991: 1 citations2001: 1 citations2002: 2 citations2003: 2 citations2005: 1 citations2007: 1 citations2008: 2 citations2009: 4 citations2010: 9 citations2011: 19 citations2012: 48 citations2013: 49 citations2014: 71 citations2015: 68 citations2016: 110 citations2017: 90 citations2018: 125 citations2019: 617 citations2020: 1,520 citations2021: 1,290 citations2022: 927 citations2023: 557 citations2024: 879 citations2025: 271 citations2026: 33 citations1990: no citations, so this year is not shown1992–2000: no citations, so these years are not shown2004: no citations, so this year is not shown2006: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,821 citing papers, 19.9% of this breakdownCanada: 718 citing papers, 7.9% of this breakdownItaly: 710 citing papers, 7.8% of this breakdownUnited Kingdom: 662 citing papers, 7.2% of this breakdownFrance: 451 citing papers, 4.9% of this breakdownNetherlands: 401 citing papers, 4.4% of this breakdownGermany: 398 citing papers, 4.4% of this breakdownChina: 368 citing papers, 4% of this breakdownSpain: 354 citing papers, 3.9% of this breakdownSwitzerland: 249 citing papers, 2.7% of this breakdownAustralia: 189 citing papers, 2.1% of this breakdownJapan: 167 citing papers, 1.8% of this breakdown
0%19.9%Other 29%

Fields

  • Medicine89.5%
  • Biochemistry, Genetics and Molecular Biology3.5%
  • Health Professions1.7%
  • Immunology and Microbiology1.5%
  • Computer Science1.2%
  • Engineering0.8%
  • Other1.8%

Topics

  • Venous Thromboembolism Diagnosis and Management16.1%
  • COVID-19 Clinical Research Studies9.9%
  • Atrial Fibrillation Management and Outcomes6.4%
  • Long-Term Effects of COVID-194.5%
  • Heparin-Induced Thrombocytopenia and Thrombosis3.2%
  • Blood Coagulation and Thrombosis Mechanisms3.1%
  • Other56.8%

Coauthors

All papers

Open in search
  1. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    Authors: , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 849

  2. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,607

  3. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 847

  4. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sam Schulman - JAMA Internal Medicine 2019 cited by 501

  5. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John W. Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A. Beckman, Philippe Gabríel Steg, Gregg W. Stone, Stephan Rosenkranz, Samuel Z. Goldhaber, Sahil A. Parikh, Manuel Monréal, Harlan M. Krumholz, Stavros Konstantinides, Jeffrey I. Weitz, Gregory Y.H. Lip - Journal of the American College of Cardiology 2020 cited by 2,939

  6. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , - BMJ 2019 cited by 313

  7. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 439

  8. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elizabeth Lorenzi, Scott Berry, Lindsay R. Berry, Aaron W. Aday, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Bihari, Shailesh, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc J. M. Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen‐Ting Chen, Allen Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Todd W. Costantini, Sophie de Brouwer, Lennie Derde, Michelle A. Detry, Abhijit Duggal, Vladimír Džavík, Mark B. Effron, Lise J Estcourt, Brendan M. Everett, Dean Fergusson, Mark Fitzgerald, Robert Fowler, J.‐P. Galanaud, Benjamin Galen, Sheetal Gandotra, Sebastián García‐Madrona, Timothy D. Girard, Lucas C. Godoy, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Greenstein, Peter L Gross, Naomi M. Hamburg, Rashan Haniffa, George P. Hanna, Nicholas Hanna, Sheila M. Hegde, Carolyn M. Hendrickson, R. Duncan Hite, Alexander Hindenburg, Aluko A. Hope, James M Horowitz, Christopher M. Horvat, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Vivek Iyer, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J. King and 78 more - 2021 cited by 589

  9. Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

    Authors: , , , , , , - Journal of Thrombosis and Haemostasis 2018 cited by 434

  10. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa Baumann Kreuziger, Abi Beane, Jeffrey S. Berger, Scott Berry, Lindsay R. Berry, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc J. M. Bonten, Charlotte Bradbury, Maria M. Brooks, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Marc Carrier, Lana A. Castelucci, Sweta Chekuri, Jen‐Ting Chen, Allen Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Aira Contreras, Todd W. Costantini, Mary Cushman, Sophie de Brouwer, Lennie Derde, Michelle A. Detry, Abhijit Duggal, Vladimír Džavík, Mark B. Effron, Heather Eng, Jorge Escobedo, Lise J Estcourt, Brendan M. Everett, Micheal E. Farkough, Dean Fergusson, Mark Fitzgerald, Rob Fowler, Joshua D. Froess, Zhuxuan Fu, J.‐P. Galanaud, Benjamin Galen, Sheetal Gandotra, Timothy D. Girard, Lucus D. Godoy, Ewan C. Goligher, Michelle N. Gong, Andrew L. Goodman, Herman Goossens, Anthony Gordon, Cameron Green, Yonatan Greenstein, Peter L. Gross, Raquel Morillo Guerrero, Naomi M. Hamburg, Rashan Haniffa, George P. Hanna, Nicholas Hanna, Sheila M. Hedge, Carolyn M. Hendrickson, Alisa M. Higgins, Alexander Hindenburg, R. Duncan Hite, Judith S. Hochman, Aluko A. Hope, James M Horowitz, Christopher M. Horvat, Brett L. Houston, David T. Huang and 111 more - JAMA 2023 cited by 98

  11. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gloria Lim, Michael Fralick, Saskia Middeldorp, Agnes Lee, Fei Zuo, Bruno R. da Costa, Kevin E. Thorpe, Elnara Márcia Negri, Mary Cushman, Peter Jüni - BMJ 2021 cited by 371

  12. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 70

  13. Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism

    Authors: , , , , , , - JACC Basic to Translational Science 2023 cited by 62

  14. McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Thrombosis and Haemostasis 2018 cited by 140

  15. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2023 cited by 75

  16. Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

    Authors: , , , - Arteriosclerosis Thrombosis and Vascular Biology 2023 cited by 68

  17. VTE Prophylaxis in Critically Ill Adults

    Authors: , , , , , , , , , , , , , , , , , , - CHEST Journal 2021 cited by 85

  18. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism

    Authors: , , , , , , , , , , - Circulation 2012 cited by 226

  19. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Thrombosis and Haemostasis 2018 cited by 214

  20. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    Authors: , , , , , , , , , , , - Thrombosis and Haemostasis 2018 cited by 211

  21. Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology

    Authors: , , , , , , , , , , , , , - Gastroenterology 2014 cited by 347

  22. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism

    Authors: , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2017 cited by 142

  23. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 58

  24. Management of cancer‐associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH

    Authors: , , , , , , - Journal of Thrombosis and Haemostasis 2018 cited by 211